New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Saturday, Nov 21, 2026
Export PASG’s income statement to Excel — free account
Passage Bio, Inc.
PASG- EPS
- n/m
- Free cash flow
- n/m
Quarter to September 2026, against a year earlier
3.92
0.31
+8.59%
Follow PASG
Alert me
Analysts’ price targets Wall Street, collected weekly
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Sep ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Gross margin, % | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | 0.0 pt | ||||||
| EBT | — | — | (13) | (46) | (112) | (185) | (136) | (102) | (65) | (46) | (33) | n/m | ||||||
| EBT margin, % | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Net income | — | 0 | (13) | (46) | (112) | (185) | (136) | (102) | (65) | (46) | (33) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | |||||
| Earnings | — | — | (0.28) | (215.46) | (58.20) | (69.60) | (50.00) | (37.20) | (21.40) | (14.35) | (10.35) | n/m | ||||||
| Cash flow | — | — | (0.41) | (188.37) | (41.70) | (47.57) | (43.44) | (28.59) | (15.58) | (9.93) | (10.14) | n/m | ||||||
| Capex | — | — | 0.00 | (7.99) | (0.85) | (9.61) | (1.94) | (0.05) | (0.01) | 0.37 | 0.01 | n/m | ||||||
| Free cash flow | — | — | (0.41) | (196.36) | (42.56) | (57.18) | (45.37) | (28.65) | (15.59) | (9.56) | (10.14) | n/m | ||||||
| Book value | — | — | (0.27) | (265.59) | 157.82 | 119.47 | 73.99 | 40.66 | 19.90 | 5.91 | 0.02 | n/m | ||||||
| Shares, m | — | — | 46 | 0 | 2 | 3 | 3 | 3 | 3 | 3 | 3 | (31.7%) | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | n/m | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | (19) | (40) | (81) | (127) | (118) | (78) | (48) | (32) | (33) | n/m | |||||
| Capex | — | — | (3) | (2) | (2) | (26) | (5) | 0 | 0 | 1 | 0 | n/m | ||||||
| Free cash flow | — | — | (19) | (42) | (82) | (153) | (123) | (78) | (48) | (30) | (33) | n/m | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | 33 | 162 | 296 | 296 | 179 | 102 | 59 | 25 | 0 | (4.1%) | |||||
| Net debt | — | — | (25) | (159) | (305) | (316) | (190) | (114) | (77) | (46) | (20) | n/m | ||||||
| Shareholders’ equity | — | — | (12) | (56) | 305 | 319 | 201 | 111 | 61 | 19 | 0 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | (76.33) | (43.04) | (44.31) | (54.28) | (45.48) | (51.80) | (51.21) | (55.28) | (69.68) | +21.1 pt | |||||
| ROIC | — | — | — | 0.00 | 0.00 | (4,024.99) | (735.76) | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | — | 37.32 | 133.38 | (90.34) | (59.48) | (52.35) | (65.29) | (75.07) | (113.78) | (212.27) | (151.1) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | 20 | 74 | 133 | 85 | 58 | 60 | 24 | — | +3.1% | |||||
| Revenue/emp, $m | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
Negative figures in brackets.
estimates
Fundamentals updated Nov 12, 2026
Passage Bio, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| QNTM Quantum Biopharma Ltd. | $12.6M | — (loss-making) | — (loss-making) | — | n/m | −197.94% (below 0%: shrinking) | 0.00% | (79,749.48%) | Compare |
| NEUP Neuphoria Therapeutics Inc. | $12.6M | — (loss-making) | — (loss-making) | — | n/m | +70.26% (above 0%: growing) | 100.00% | 43,872.18% | Compare |
| DYAI Dyadic International Inc. | $12.5M | — (loss-making) | — (loss-making) | −61.44% (below 0%: shrinking) | n/m | +19.88% (above 0%: growing) | 16.48% | (403.56%) | Compare |
| CASIF CASI Pharmaceuticals Inc. | $12.4M | — (loss-making) | — (loss-making) | −45.93% (below 0%: shrinking) | n/m | — | 51.14% | (147.67%) | Compare |
| JSPR Jasper Therapeutics, Inc. | $11.9M | — (loss-making) | — | — | n/m | +67.81% (above 0%: growing) | 0.09% | (1,802.16%) | Compare |
| BCDA BioCardia, Inc. | $11.7M | — (loss-making) | — (loss-making) | −93.02% (below 0%: shrinking) | n/m | −2.93% (below 0%: shrinking) | 100.00% | (54,966.67%) | Compare |
| PASG Passage Bio, Inc. | $11.6M | — (loss-making) | — | — | n/m | +17.68% (above 0%: growing) | 0.00% | — | |
| AEON AEON Biopharma, Inc. | $11.2M | — (loss-making) | — | — | n/m | −120.53% (below 0%: shrinking) | — | — | Compare |
| PBM Psyence Biomedical Ltd. | $10.9M | 0.1× | — | — | n/m | −1,628.07% (below 0%: shrinking) | — | — | Compare |
| Median of peers | $12.2M | — | — | −61.44% | — | −2.93% | 33.81% | (1,102.86%) |
Pay and ownership Proxy statement filed Apr 7, 2026
Chief executive’s pay
| Year | Total pay | Actually paid | $100 invested |
|---|---|---|---|
| 2025 | 1.49m | 1.53m | 58.00 |
| 2024 | 1.64m | 902.53k | 56.00 |
Ownership
Directors and executive officers, together
4.90%
Lynx1 Capital Management LP
19.40%
Vestal Point Capital, LP
9.50%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards
at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s
shares at the start of the earliest year shown was worth at each year’s end.
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement
Passage Bio, Inc. (PASG) Latest News
- Remix to go public in reverse merger with once high-flying Passage Bio biopharmadive.com
- PASG Stock Slumps 16% After-Hours — What’s Driving The Selloff? Stocktwits
- Passage Bio and Remix Therapeutics Announce Merger Agreement GlobeNewswire
- Passage Bio Faces Tougher FDA Road After Trial Shift, Wedbush Says
- Passage Bio Reports Updated Interim Data from upliFT-D Trial and Provides Regulatory and Corporate Updates
- Passage Bio Reports Third Quarter 2025 Financial Results and Provides Recent Business Highlights GlobeNewswire
- Wall Street Analysts Think Passage Bio (PASG) Could Surge 731%: Read This Before Placing a Bet
- Wall Street Analysts Believe Passage Bio (PASG) Could Rally 1415.15%: Here's is How to Trade Zacks
- Passage Bio Reports Second Quarter 2025 Financial Results and Provides Recent Business Highlights
- Passage Bio Reports Updated Interim Data from upliFT-D Study and Provides Program Update GlobeNewswire
20 more headlines
- Passage Bio Seen as Undervalued Despite FDA Setback, Oppenheimer Says
- Passage Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Recent Business Highlights GlobeNewswire
- Passage Bio to Present at Guggenheim Securities 2nd Annual Healthcare Innovation Conference GlobeNewswire
- Passage Bio Announces 1-for-20 Reverse Stock Split GlobeNewswire
- Passage Bio Reports First Quarter 2025 Financial Results and Provides Recent Business Highlights
- Passage Bio (PASG) Upgraded to Buy: Here's What You Should Know Zacks
- Passage Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Highlights
- Passage Bio Announces Interim Data from upliFT-D Study in FTD-GRN and Provides Business Updates
- Will Passage Bio (NASDAQ:PASG) Spend Its Cash Wisely? Simply Wall St.
- Passage Bio assumed with an Outperform at Wedbush TipRanks
- Update: Wedbush Raises Price Target on Passage Bio to $4 From $3, Keeps Outperform Rating MT Newswires
- Passage Bio Achieves Milestones in Gene Therapy Trials
- Passage Bio Reports Third Quarter 2024 Financial Results and Provides Recent Business Highlights
- Passage Bio to Present at Guggenheim Securities Healthcare Innovation Conference
- Passage Bio Presents Preclinical and Interim Clinical Data for PBFT02 in FTD-GRN at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Conference GlobeNewswire
- Passage Bio to Present at Chardan’s 8th Annual Genetic Medicines Conference GlobeNewswire
- Orbimed Advisors LLC Reduces Stake in Passage Bio Inc GuruFocus.com
- Passage Bio to Present Positive Interim Data from Cohort 1 Patients with FTD-GRN in upliFT-D Study at 14th International Conference on Frontotemporal Dementias (ISFTD2024) GlobeNewswire
- Passage Bio Welcomes Tom Kassberg to Board of Directors GlobeNewswire
- Passage Bio to Present at H.C. Wainwright 26th Annual Global Investment Conference GlobeNewswire